The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 11, 2022

Filed:

Mar. 23, 2017
Applicants:

Research Triangle Institute, Research Triangle Park, NC (US);

The Regents of the University of California, Oakland, CA (US);

Inventors:

Scott Runyon, Hillsborough, NC (US);

Danni Harris, Boonville, CA (US);

Rainer Reinscheid, Irvine, CA (US);

Yanyan Zhang, Morrisville, NC (US);

Carla Hassler, Durham, NC (US);

Assignee:

Research Triangle Institute, Research Triangle Park, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 5/068 (2006.01); A61K 38/00 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); C07K 5/097 (2006.01); C07K 5/08 (2006.01); C07K 5/103 (2006.01); C07K 7/06 (2006.01); C07K 5/107 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 3/04 (2006.01); A61P 25/18 (2006.01);
U.S. Cl.
CPC ...
C07K 5/06086 (2013.01); A61K 38/00 (2013.01); A61P 3/04 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01); C07K 5/0804 (2013.01); C07K 5/0812 (2013.01); C07K 5/0821 (2013.01); C07K 5/0827 (2013.01); C07K 5/101 (2013.01); C07K 5/1016 (2013.01); C07K 7/06 (2013.01);
Abstract

Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.


Find Patent Forward Citations

Loading…